International Biotechnology Trust: M&A activity on the rise

Hardman & Co

International Biotechnology Trust plc (LON:IBT) was established in 1994 to provide institutional and retail investors with the opportunity to participate in global biotechnology and life science companies, from venture-stage development via venture capital (SV Health Investors) funds through to global, multinational biotechnology companies. The main aim of the trust is to generate capital growth, while minimising risk, through a diversified portfolio and an experienced investment team. Over the last five years, IBT’s NAV per share has increased 25%, while the share price has increased 32% over the same period – the superior returns generally reflected by a reduction in the share price discount.

  • Strategy: International Biotechnology Trust’s investment objective is to achieve long-term capital growth by investing in biotechnology companies that address unmet medical needs. The trust offers a diversified portfolio of listed and private companies on a global basis, although the vast majority (88%) of investments are currently in the US.
  • NAV updates: With ca.90% of the investment portfolio in listed companies, the NAV changes on a daily basis, which is updated on IBT’s website. The company also produces monthly factsheets, which highlight portfolio changes and update the NAV (https://ibtplc.com/investor#factsheets). The managers also publish an informative topical blog each month (https://ibtplc.com/investor#investment-blog).
  • Portfolio management: Over the past six to nine months, the valuations of biotech companies have been correcting. In anticipation of this, the managers increased their holdings in the safer mega-cap companies and reduced exposure to the small- to mid-cap companies. Now that valuations have become more reasonable, the managers have been reversing these positions, as they see superior growth and increased potential for M&A in these smaller companies.
  • Risks: Risk is minimised through portfolio diversification, geographical spread and active specialist investment management. In addition, many valuation inflection points in the drug industry are around the time of binary outcomes (e.g. clinical trial results) – so the trust aims to reduce the fund’s exposure to such events that it considers binary.
  • Investment summary: International Biotechnology Trust provides investors with the opportunity to participate in the drug industry, from early-stage development through to full commercialisation of regulatory approved drugs. The focus is on companies that address unmet medical needs. The five-year CAGR in NAV has been 4.6%, reflected in the share price CAGR of 5.7% over the same period, and the trust pays an annual dividend of 4% of NAV at the preceding financial year-end.
You might also enjoy reading  Arbuthnot Banking relationship banking benefits when interest rates rise (VIDEO)

DOWNLOAD THE FULL REPORT

Find more news, interviews, share price & company profile here for:
Hardman & Co

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index